Novakand Pharma AB
3EE0
Company Profile
Business description
Novakand Pharma AB is developing a new class of innovative drugs focusing on inflammatory diseases and cancer. The company is developing a new class of small molecule drugs that control disease promoting immune cells with precision, by targeting the fractalkine axis.
Contact
Nanna Svarts vag 4
Solna171 65
SWET: +46 850126080
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
5
Stocks News & Analysis
stocks
Cheap Narrow Moat ASX share continues to face negative sentiment
Earnings growth fails to excite investors worried about AI disruption.
stocks
ASX energy giant remains cheap following record production
Impressive cost control and record production leads to higher dividend.
stocks
Strong results from cheap ASX share
The market responded favourably to results but shares still underpriced.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,359.00 | 50.70 | 0.54% |
| CAC 40 | 8,519.21 | 22.04 | 0.26% |
| DAX 40 | 24,986.25 | 5.72 | -0.02% |
| Dow JONES (US) | 49,174.50 | 370.44 | 0.76% |
| FTSE 100 | 10,680.59 | 4.15 | -0.04% |
| HKSE | 26,738.90 | 148.58 | 0.56% |
| NASDAQ | 22,863.68 | 236.41 | 1.04% |
| Nikkei 225 | 58,583.12 | 1,262.03 | 2.20% |
| NZX 50 Index | 13,525.58 | 6.73 | -0.05% |
| S&P 500 | 6,890.07 | 52.32 | 0.77% |
| S&P/ASX 200 | 9,128.30 | 44.20 | 0.49% |
| SSE Composite Index | 4,147.23 | 29.82 | 0.72% |